Technical / White Paper

Smart strategies for sustained release matrix tablets: Compritol® 888 ATO

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This content is provided by Gattefossé, and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com

Smart strategies for sustained release matrix tablets: Compritol® 888 ATO

This white paper gives an overview of how Compritol®​ 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.

We provide an insight on formulation critical attributes, how Compritol®​ can be used in a range of production processes and how process flexibility can leverage formulation simplification or provide approaches for overcoming formulation challenges or alternatively, enable the development of innovative drug delivery systems.

At Gattefossé we aim to share our knowledge to help formulators use lipid excipients to their best advantage.  

Latest content from Gattefossé

SEDDS for oral peptide delivery: Gattefossé insight

Content provided by Gattefossé

SEDDS for oral peptide delivery: Gattefossé insight

Peptide therapeutics are on the rise due to their high potency, specific mode of action and safety. Currently, more than 60 peptides are available on the market. About 140 are in clinical trials and 500 are in preclinical development (Fosgerau and Hoffmann,...

Supplier info centre